Palbociclib in Real World Practice

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

NCT05584644 ·Status: COMPLETED

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

NCT04671615 ·Status: COMPLETED

Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

NCT04937660 ·Status: COMPLETED

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

NCT04460911 ·Status: COMPLETED

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481 ·Status: COMPLETED

Patterns of Prescribing and Monitoring of Palbociclib

NCT03285568 ·Status: COMPLETED

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

NCT02679755 ·Status: COMPLETED ·Phase: PHASE4

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898 ·Status: COMPLETED

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

NCT03560856 ·Status: UNKNOWN ·Phase: PHASE2

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

NCT05155566 ·Status: COMPLETED

Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period

NCT05135104 ·Status: UNKNOWN

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

NCT02297438 ·Status: COMPLETED ·Phase: PHASE3

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

NCT04874025 ·Status: COMPLETED

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

NCT06003114 ·Status: COMPLETED

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

NCT04318223 ·Status: UNKNOWN ·Phase: PHASE2

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

NCT03609047 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

NCT02600923 ·Status: COMPLETED ·Phase: PHASE3

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

NCT01740427 ·Status: COMPLETED ·Phase: PHASE3

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

NCT04394247 ·Status: COMPLETED

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

NCT06338644 ·Status: NOT_YET_RECRUITING

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

NCT03809988 ·Status: COMPLETED ·Phase: PHASE2

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

NCT02536742 ·Status: COMPLETED ·Phase: PHASE2

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

NCT04858997 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

NCT04060862 ·Status: TERMINATED ·Phase: PHASE1

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

NCT02894398 ·Status: COMPLETED ·Phase: PHASE2